Researcher:
Kocatürk Göncü, Özgür Emek

Profile Picture
ORCID

Job Title

Faculty Member

First Name

Özgür Emek

Last Name

Kocatürk Göncü

Name

Name Variants

Kocatürk Göncü, Özgür Emek

Email Address

Birth Date

Filters

2019 - 201932020 - 202338

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.ac3fc5b8-1baf-44c2-be13-4d37da910e6a

Search Results

Now showing 1 - 10 of 43
  • Placeholder
    PublicationMetadata only
    An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria
    (Elsevier, 2022) Ornek, Sinem Ayse; Orcen, Cihan; Church, Martin K.; N/A; Kocatürk Göncü, Özgür Emek; Faculty Member; School of Medicine; 217219
    Background: Guidelines recommend standard doses of antihistamines as first-line, and updosing of antihistamines as second-line treatment for the management of chronic urticaria (CU). However, remission rates with different types of first- and second-line treatments and indicators of antihistamine response are largely lacking in the literature.Objectives: To examine response rates to first- and second-line treatments in CU, and to identify patient characteristics that can predict antihistamine treatment outcomes.Methods: We retrospectively analyzed treatment outcomes of 657 CU (556 chronic spontaneous urticaria (CSU), 101 chronic inducible urticaria (CIndU)) patients who had at least 3-months of follow-up data.Results: A standard dose of second generation antihistamines (sgAH) was effective in 43.1 % of the patients. An additional 28.8 % of patients were in remission with second-line treatments. Among patients whose disease was in remission with a standard dose of sgAHs, 14.8 % benefited from switching from their current sgAH to another sgAH. Updosing sgAHs, combination of two different sgAHs, sgAH and first generation H1-antihistamine combination, and sgAH and leukotriene receptor antagonist combination provided remission in 38.3 %, 35.8 %, 37.5 % and 25 % of patients who were given these treatments, respectively. Baseline UCT score <= 4, emergency referral and family history of CSU were found to be risk factors for antihistamine refractoriness in patients with CSU.Conclusions: A step-wise approach to the management of CU is practical as more patients respond to treatment at each step. The presence of baseline UCT score <= 4, emergency referral and family history of CSU might be helpful to determine patients who require third-line treatments in advance.
  • Placeholder
    PublicationMetadata only
    Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: clinical features, associated conditions and indicators of treatment response
    (John Wiley and Sons Inc, 2023) Özçeker, Deniz; Can, Pelin Kuteyla; Terzi, Özlem; Örnek, Sinem Ayşe; Değirmentepe, Ece Nur; Kızıltaç, Kübra; Saraç, Esra; Kocatürk Göncü, Özgür Emek; Faculty Member; Faculty Member; School of Medicine; School of Medicine; 172724; 217219
    Background: Chronic spontaneous urticaria (CSU) is a common disease both in the pediatric and in the adult population. However, there are differences between the two patient populations with respect to etiological factors, comorbidities, and treatment responses. Our aim was to determine differences between pediatric and adult CSU in terms of clinical characteristics, laboratory parameters, comorbidities, response to treatment, and indicators of response. Methods: A retrospective analysis of CSU patients was performed. Data regarding differences between pediatric and adult CSU patients were analyzed. Indicators of treatment response were determined separately in both pediatric and adult patients. Results: Of 751 CSU patients (162 pediatrics and 589 adults), female dominancy (48.8% vs. 69.6%) and rate of angioedema (19.1% vs. 59.8%) were lower, and disease duration (5 months vs. 12 months) was shorter in pediatric patients. Anti-TPO positivity (24.7% vs. 9%), elevated CRP (46.5% vs. 11.1%), eosinopenia (38.5% vs. 18.1%), and skin prick test positivity (39.3% vs. 28.8%) were significantly more frequent in adult patients. Response to antihistamines was higher in the pediatric group, and only 7% used omalizumab versus 20.8% in the adults. The comparisons were also performed between <12-year and ≥12-year patients and yielded similar results. Conclusion: Pediatric CSU shows distinct characteristics such as lower incidence of angioedema and antithyroid antibodies, and it responds better to antihistamines. These suggest that CSU becomes more severe and refractory in adolescents and adults. Adolescent CSU shows features similar to adult CSU rather than pediatric CSU.
  • Placeholder
    PublicationMetadata only
    The benefit of complete response to treatment in patients with chronic spontaneous Urticaria—CURE results
    (Elsevier, 2023) Kolkhir, Pavel; Laires, Pedro A.; Salameh, Pascale; Asero, Riccardo; Bizjak, Mojca; Košnik, Mitja; Dissemond, Joachim; van Doorn, Martijn; Hawro, Tomasz; Kasperska-Zajac, Alicja; Zajac, Magdalena; Peter, Jonny; Parisi, Claudio A.S.; Ritchie, Carla A.; Kulthanan, Kanokvalai; Tuchinda, Papapit; Fomina, Daria; Kovalkova, Elena; Khoshkhui, Maryam; Kouzegaran, Samaneh; Papapostolou, Niki; Du-Thanh, Aurélie; Kamegashira, Akiko; Meshkova, Raisa; Vitchuk, Alexander; Bauer, Andrea; Grattan, Clive; Staubach, Petra; Bouillet, Laurence; Giménez-Arnau, Ana M.; Maurer, Marcus; Weller, Karsten; Kocatürk Göncü, Özgür Emek; Faculty Member; School of Medicine; 217219
    Background and Objective: Chronic spontaneous urticaria (CSU) is a distressing disease. We report real-world data from the global Chronic Urticaria Registry (CURE) about associations between various CSU states and sleep impairment, plus important health-related quality-of-life (HRQoL) outcomes and compared different methods to assess CSU states. Methods: CURE data were collected at baseline and 6-monthly follow-ups (FU). Assessments included CSU states using the Urticaria Control Test (UCT), weekly Urticaria Activity Score (UAS7), and Physician Global Assessment (PhyGA) of treatment response. Complete response to treatment (CR, UAS7 = 0), complete control of disease (CC, UCT = 16), and PhyGA = CR were assessed, plus the Dermatology Life Quality Index and the Chronic Urticaria Quality-of-Life Questionnaire (CU-Q2oL) sleep domain. Results: Overall, 2078 patients were included. At baseline, 9.8%, 17.9%, and 42.3% of patients had UCT = 16, UAS7 = 0, or PhyGA = CR, respectively, which increased at FU1 and FU2. Patients with higher UCT scores had better sleep and HRQoL. The presence of angioedema without wheals, episodic disease, omalizumab treatment, and male sex were associated with CC (P <.05). Among 469 patients who achieved CC or CR, 16.4% (n = 77) showed CC or CR with all 3 instruments. Agreement between UCT = 16 and UAS7 = 0 measurements was moderate (κ = 0.581), but poor between UCT = 16 and PhyGA = CR (κ = 0.208). Conclusions: Few patients had CR/CC of their CSU at baseline entry. Disease control strongly related to good sleep and better HRQoL; therefore, it is important to aim for CR in CSU treatment. Patient-reported UCT and UAS7 assessments demonstrated a more accurate measurement of CSU state versus physician assessments.
  • Placeholder
    PublicationMetadata only
    Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment
    (Wiley, 2021) Turk, Murat; Yilmaz, Insu; Bahcecioglu, Sakine Nazik; Can, Pelin; Ertas, Ragip; Kartal, Demet; Cinar, Salih Levent; N/A; Kocatürk Göncü, Özgür Emek; Faculty Member; School of Medicine; 217219
    The question how second-generation antihistamines (sgAHs) should be used when chronic spontaneous urticaria (CSU) is under control with omalizumab is still unanswered. This study aimed to investigate the effectiveness of as-needed sgAHs in patients with well-controlled urticaria under omalizumab treatment. Patients from four different urticaria centers who were treated with omalizumab 300 mg/4 weeks for at least 3 months, had well-controlled urticaria (Urticaria Control Test: 16 > UCT >= 12) and were using sgAHs only if needed, were included in this study. In order to assess effectiveness of sgAHs, change in the itch, hives, and total itch-hives scores before and after sgAHs were evaluated using modified urticaria activity score-twice daily. Fifty-three patients [38 female (71.7%)] with mean age 41.1 +/- 11.4 years were included in this study. Median sgAH intake per patient throughout the 4 week-intervals was 3 (2-5) tablets. sgAH intake decreased itch, hives and total itch-hives scores 45.7% +/- 52.9, 42.4% +/- 39.1, and 50.2% +/- 51.1, respectively (P < .001 for all). This decrease was similar in both isolated-urticaria and urticaria-and-angioedema phenotypes. Baseline IgE levels were positively correlated with the decrease of three symptom scores (r = 0.31, P = .05; r = 0.375, P = .017; r = 0.31, P = .05, respectively) that showed in patients with higher baseline total IgE levels, as needed sgAH intake decreased the symptom scores less. Our study showed that sgAHs may still be an effective option for the treatment of the intermittent symptoms in patients with well-controlled urticaria under omalizumab treatment. Baseline total IgE levels may be used as a potential biomarker for sgAH effectiveness in these patients.
  • Placeholder
    PublicationMetadata only
    Effect of a pseudoallergen-free diet in chronic spontaneous urticaria: a pilot study
    (Bilimsel Tip Yayinevi) Can, Pelin Kuteyla; Saraç, Esra; Kocatürk Göncü, Özgür Emek; Faculty Member; Faculty Member; School of Medicine; 172724; 217219
    Objective: The role of dietary factors in the etiopathogenesis of chronic spontaneous urticaria (CSU) has been a matter of discussion and it is widely accepted that most urticaria cases triggered by food are caused by pseudoallergic reactions. In this prospective study, our aim was to investigate the effect of a pseudoallergen-free diet (PAFD) on disease activity, the need for antihistamine use, and the quality of life in patients with CSU. Materials and Methods: The study included adult patients who were on follow up for CSU for a duration of at least 6 months and had symptoms every day or every other day. The patients were given a food diary, which also included assessment of daily disease activity. The daily Urticaria Activity Score (UAS), the Chronic Urticaria Quality of Life Questionnaire score at baseline and at the 4th week, and frequency of antihistamine use were obtained. According to the change in UAS (Delta UAS), the patients' response to PAFD was classified as strong (Delta UAS >= 8), partial (8>Delta UAS >= 4), or no response (Delta UAS<4). Results: Twenty-three patients, 19 females (82.6%) and 4 males (17.4%), completed the study, the mean age was 43 +/- 4.6 years. According to Delta UAS, 6 patients (26.1%) had strong response, 6 (26.1%) had partial response, and 11 (47.8%) were unresponsive to PAFD. The mean Delta UAS value of the patients who responded to PAFD was 8.1 (min:4, max:15). At the end of the study, 9 (39.1%) patients had a significant improvement in their quality of life. There were 6 (26%) patients who both responded to PAFD and had improved quality of life scores. The frequency of antihistamine use decreased in 10 (43.5%) patients. Conclusion: PAFD may help decrease disease activity in CSU. We observed that the frequency of antihistamine use could be reduced and the patient's quality of life could be improved by adding PFAD to antihistamine therapy.
  • Placeholder
    PublicationMetadata only
    Serum clusterin levels are not associated with chronic spontaneous urticaria regardless of serum lipids
    (Edizioni Minerva Medica, 2022) Vurgun, Eren; Etikan, Pırıl; Güntaş, Gülcan; Kocatürk Göncü, Özgür Emek; Memet, Bachar; Faculty Member; Doctor; School of Medicine; N/A; N/A; Koç University Hospital; 217219; N/A
    Background: Clusterin is related to immunity and inflammation via regulation of complement activation and bidirectional regulation, and by major proinflammatory cytokines. Clusterin levels have been the subject of a few research both in patients with hyperlipidemia and those with chronic spontaneous urticaria (CSU) separately. The aims of this study were to evaluate the levels of clusterin levels and serum lipids and the relationships between them in patients with CSU. Methods: Fifty patients with CSU and 30 healthy controls were enrolled into the study. The activity of urticaria of the patients was determined by urticaria activity score (UAS7). Serum clusterin, total cholesterol, HDL, LDL and triglyceride levels of the participants were measured and compared. The relationships between UAS, lipids and clusterin were examined. Results: There was no difference in clusterin levels between CSU patients and controls. Clusterin level was not related to activity of urticaria. Clusterin levels were not correlated with any of lipid parameters neither in CSU patients nor in controls. Conclusions: Findings of this study show that clusterin levels do not change due to CSU. Serum clusterin levels cannot be used as a diagnostic or a disease activity marker in CSU patients, regardless of the lipid profile.
  • Placeholder
    PublicationMetadata only
    The prevalence of metabolic syndrome and the risk of coronary artery disease development in chronic spontaneous urticaria assessed by the framingham risk score
    (Wiley-Blackwell, 2020) Özdemir, O.; Kuteyla Can, Pelin; Kocatürk Göncü, Özgür Emek; Faculty Member; School of Medicine; 217219
    N/A
  • Placeholder
    PublicationMetadata only
    Chronic spontaneous urticaria: the role and relevance of autoreactivity, autoimmunity, and autoallergy
    (Elsevier, 2023) Asero, Riccardo; Ferrer, Marta; Maurer, Marcus; Kocatürk Göncü, Özgür Emek; Faculty Member; School of Medicine; 217219
    Chronic spontaneous urticaria (CSU) is a frequent and often severely disabling disease. A large number of studies were performed during the last 2 decades to clarify its pathogenesis. These studies shed light on the underlying autoimmune mechanisms of CSU pathogenesis and have led us to understand that different mechanisms may exist and, sometimes, coexist behind the same clinical presentation. The present article reviews the meaning of the terms autoreactivity, autoimmunity, and autoallergy, which have been variably used over the years to define different endotypes of the disease. Furthermore, we discuss the methods potentially able to lead us to the correct classification of CSU patients.
  • Placeholder
    PublicationMetadata only
    Angioedema indicates a different endotype of chronic spontaneous urticaria
    (Bilimsel Tip Yayinevi, 2022) Ornek, Sinem; N/A; Kocatürk Göncü, Özgür Emek; Faculty Member; School of Medicine; 217219
    Objective: Chronic spontaneous urticaria (CSU) is characterized by urticarial plaques and/or deeply seated swellings (angioedema) persisting for more than 6 weeks. Angioedema accompanies approximately half of CSU patients, however data on the clinical significance of angioedema is sparse. In our study, we aimed to investigate whether CSU cases accompanied by angioedema (CSUwAE) differ from CSU cases without angioedema (CSUwoAE) in terms of clinical features, treatment responses and associated conditions. Materials and Methods: We retrospectively examined the medical records of chronic urticaria patients who were referred to the Urticaria Center of Reference and Excellence of Okmeydani Training and Research Hospital between January 2013 and July 2019, and included CSU patients who had at least 3 months of follow up data and Urticaria Control Test (UCT) scores at the 0 and 12th weeks in the study. We obtained demographic, clinical and laboratory characteristics of the patients and the treatments they received from the patient files. We evaluated the effectiveness of treatment using UCT. We compared data between CSUwAE and CSUwoAE cases. Results: A total of 556 CSU patients were included in the study. Of all, 57% was CSUwAE and 43% was CSUwoAE. More CSUwAE patients had a disease duration of more than 5 years (p=0.031); and emergency admission, non-steroidal anti-inflammatory drug intolerance, autologous serum skin test positivity, and increased C-reactive protein values were found more frequently in CSUwAE cases (p<0.001; p=0.011; p<0.001; p=0.009, respectively). The skin prick test positivity rate was higher in CSUwoAE cases (p=0.043). The overall remission rates were lower in CSUwAE (p=0.009). Resistance to both standard doses of antihistamines and need for third-line treatments were more frequent in CSUwAE (p=0.004; p=0.009, respectively). Conclusion: Angioedema is a feature of antihistamine refractory, severe CSU with longer disease duration and might be an indicator of autoimmune CSU.
  • Placeholder
    PublicationMetadata only
    Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: statement of Dermatoallergy Working Group of the Turkish Society of Dermatology
    (Istanbul Assoc. of Dermatology and Venerology, 2019) Salman, Andaç; Atakan, Nilgün; Başkan, Emel Bülbül; Borlu, Murat; Canpolat, Filiz; Erdem, Teoman; Erdem, Yasemin; Gül, Ülker; Kartal, Selda Pelin; Koca, Rafet; Küçük, Özlem Su; Öğretmen, Zerrin; Özkaya, Esen; Sarıcaoğlu, Hayriye; Şavk, Ekin; Taşkapan, Oktay; Utaş, Serap; Alper, Fatma Sibel; Kocatürk Göncü, Özgür Emek; Faculty Member; Faculty Member; School of Medicine; 118467; 217219
    N/A